25 completed, 6 recruiting, 6 terminated, 5 not yet recruiting. 48 Phase 1, 8 Phase 2.
Follow Spondylarthropathies: new trials by email Literature Review of Spondylarthropathies trials Research Report on Spondylarthropathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ia Study of MST-931 in Healthy Adult Subjects MST-931, MST-931 Placebo - Ankylosing Spondylitis (AS) | Phase 1 | Recruiting | Mabsoft Therapeutics (Shanghai) Co., Ltd. | 32 | 2026-11-30 | 2026-11-03 |
| Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation Apremilast XR, Apremilast IR - Psoriasis, Arthritis, Psoriatic | Phase 1 | Not yet recruiting | Amgen | 114 | 2026-11-18 | 2026-11-02 |
| A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male Participants DRL_AB - Healthy Volunteers | Phase 1 | Not yet recruiting | Dr. Reddy's Laboratories Limited | 160 | 2026-08-19 | 2026-08-04 |
| Safety and Efficacy of Allogeneic Bone Marrow MSCs in Ankylosing Spondylitis IV administration of CG-BM1, Placebo, CG-BM1 - Ankylosing Spondylitis | Phase 1 | Not yet recruiting | Eighth Affiliated Hospital, Sun Yat-sen University | 40 | 2026-07-01 | 2026-06-08 |
| Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease S-4321 - Autoimmune Diseases, Rheumatoid Arthritis (RA) | Phase 1 | Recruiting | Seismic Therapeutic AU Pty Ltd | 24 | 2026-06-01 | 2026-06-01 |
| A Phase I/Ⅱ Clinical Trial for Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Ankylosing Spondylitis HS_SW01 cells injection - Ankylosing Spondylitis | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Huishan Biotechnology Co., Ltd. | 18 | 2026-04-10 | 2026-04-20 |
| A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc - Psoriatic Arthritis, Axial Spondyloarthritis | Phase 1 | Recruiting | UCB Biopharma SRL | 392 | 2025-12-10 | 2026-07-06 |
| A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) Bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis | Phase 1 | Recruiting | UCB Biopharma SRL | 20 | 2025-11-05 | 2026-09-18 |
| EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1) Part A - Single Ascending Dose (SAD) in Healthy Human Volunteers, Part B - Multiple Ascending Dose (MAD) in participants with axSpA, Part C - Safety expansion cohort in participants with axSpA - Axial Spondyloarthritis (AxSpA) | Phase 1 / Phase 2 | Recruiting | Grey Wolf Therapeutics | 140 | 2025-07-28 | 2026-09-18 |
| Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases Mesenchymal Stem Cells, Placebo - Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE) | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 200 | 2025-02-01 | 2025-03-21 |
| Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis LPX-TI641, Placebo - Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) | Phase 1 | Active not recruiting | LAPIX Therapeutics Inc. | 48 | 2024-12-15 | 2026-10-30 |
| Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis Allocetra - Arthritis, Psoriatic | Phase 1 | Terminated | Enlivex Therapeutics Ltd. | 5 | 2024-08-01 | 2026-04-13 |
| A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis si-544, Placebo - Psoriasis Vulgaris, Psoriatic Arthritis | Phase 1 | Completed | selectION Therapeutics GmbH | 45 | 2024-01-22 | 2025-07-03 |
| Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Ankylosing Spondylitis Human Umbilical Cord Mesenchymal Stem Cells - Ankylosing Spondylitis | Phase 1 | Not yet recruiting | Asia Cell Therapeutics (Shanghai) Co., Ltd. | 9 | 2023-08-30 | 2023-08-15 |
| A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi® BAT2506 injection, Simponi® (EU commercially available product), Simponi® (US commercially available product) - Psoriatic Arthritis | Phase 1 | Completed | Bio-Thera Solutions | 375 | 2022-08-01 | 2023-08-28 |
| A Clinical Study With Adalimumab Biosimilar Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product] - Pharmacokinetics, Safety Issues | Phase 1 | Completed | Laboratorios Richmond S.A.C.I.F. | 150 | 2022-08-01 | 2024-03-04 |
| Small Changes Behavioural Weight Loss Treatment Approach for Psoriatic Arthritis Patients With Comorbid Obesity BWLT, Waitlist Control for BWLT - Psoriatic Arthritis, Obesity | Phase 1 | Completed | University of Calgary | 38 | 2022-02-01 | 2023-12-14 |
| A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis Guselkumab, Risankizumab - Arthritis, Psoriatic, Healthy | Phase 1 | Terminated | Janssen Research & Development, LLC | 11 | 2021-11-04 | 2022-07-26 |
| An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients Secukinumab 300 MG, Secukinumab 150 MG, Methotrexate - Psoriatic Arthritis | Phase 1 | Unknown | Peking Union Medical College Hospital | 60 | 2021-07-15 | 2021-07-20 |
| Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 PurWet, FurFat, PurApo - Sequelae of; Infection, Post Infection Glomerulonephritis | Phase 1 / Phase 2 | Unknown | All Natural Medicine Clinic, LLC | 2000 | 2021-03-01 | 2021-05-26 |
Showing 20 of 48. Sign in to see all of them.
Arthritis, Psoriatic (31) · Spondylitis, Ankylosing (18) · Arthritis, Rheumatoid (14) · Psoriasis (8) · Axial Spondyloarthritis (7) · Autoimmune Diseases (6) · Crohn Disease (6) · Arthritis, Juvenile (4) · Inflammatory Bowel Diseases (4) · Lupus Erythematosus, Systemic (4) · Arthritis (3) · Colitis, Ulcerative (3) · Hidradenitis Suppurativa (3) · Arthritis, Reactive (2) · Dermatomyositis (2)
Bone Diseases (48) · Musculoskeletal Diseases (48) · Spinal Diseases (48) · Spondylarthritis (48) · Spondylitis (48) · Joint Diseases (47) · Arthritis (45) · Skin and Connective Tissue Diseases (35) · Skin Diseases (33) · Skin Diseases, Papulosquamous (32) · Psoriasis (24) · Ankylosis (23) · Immune System Diseases (18) · Connective Tissue Diseases (17)
Infliximab (3) · deucravacitinib (3) · Certolizumab Pegol (2) · Methotrexate (2) · bimekizumab (2) · Adalimumab (1) · BCD-055 (1) · CTLA-4 Antigen (1) · GSK3050002 (1) · Ipilimumab (1) · Leflunomide (1) · Leucovorin (1) · Nivolumab (1) · Platinum Compounds (1) · Rituximab (1)
Bristol-Myers Squibb (4) · UCB Biopharma SRL (3) · Bio-Thera Solutions (2) · Celltrion (2) · UCB BIOSCIENCES, Inc. (2) · Advanced Accelerator Applications (1) · All Natural Medicine Clinic, LLC (1) · Amgen (1) · Asia Cell Therapeutics (Shanghai) Co., Ltd. (1) · Biocad (1) · Dr. Reddy's Laboratories Limited (1) · Eighth Affiliated Hospital, Sun Yat-sen University (1) · Enlivex Therapeutics Ltd. (1) · Eveliqure Biotechnologies GmbH (1) · Fresenius Kabi SwissBioSim GmbH (1)
United States (15) · China (6) · Netherlands (6) · Germany (5) · Switzerland (5) · Australia (4) · Canada (4) · Spain (3) · Bulgaria (2) · France (2) · New Zealand (2) · Poland (2) · South Korea (2) · United Kingdom (2) · Argentina (1)
Won Park, M.D., Ph.D. (2) · Alison Heald, MD (1) · Andreas Klostermann, Dr. (1) · Chunde Bao (1) · Ethel C. Feleder, MD (1) · Fei Sun, MD (1) · Hussein A Tawbi (1) · Ivanov Roman, PhD (1) · Jennifer Martin, MD (1)
PMID 19587341, PMID 20231202, PMID 26795209, PMID 27117698, PMID 28814432, PMID 29030361, PMID 29275332, PMID 32905628, PMID 33207794, PMID 33241960, PMID 35262901, PMID 35470301, PMID 42012633
2017 (2), 2023 (1), 2025 (1), UM1CA186688 (1)